Effect of icosapent ethyl on coronary Fat Attenuation Index score in high-risk, statin treated patients with established cardiovascular disease and elevated plasma triglycerides (IRIS-FAI)

Research summary

DESIGN An open label,pilot trial with a 12 month treatment period with randomisation to either IPE or standard of care. PRIMARY OBJECTIVE To evaluate the impact of icosapent ethyl (IPE) treatment on coronary inflammation - assessed by Fat Attenuation Index (FAI) Score. The hypothesis is that targeted treatment of participants with high vascular inflammation with IPE guided by the FAI-Score or CaRi-Heart® reduces vascular inflammation to a greater extent compared to the standard of care treatment in the NICE Guidelines.

Principal Investigator

Prof Charalambos Antoniades

Contact us

Email: cvm_nurses@cardiov.ox.ac.uk

IRAS number

1009727